Erythromycin estolate - Generic Drug Details

What are the generic sources for erythromycin estolate and what is the scope of freedom to operate?

Erythromycin estolate is the generic ingredient in three branded drugs marketed by Barr, Ivax Sub Teva Pharms, Watson Labs, Lilly, Dista, Alpharma Us Pharms, Cosette Pharms Nc, and Life Labs, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for erythromycin estolate.

Summary for erythromycin estolate

US Patents:	0
Tradenames:	3
Applicants:	8
NDAs:	14
Drug Master File Entries:	19
Raw Ingredient (Bulk) Api Vendors:	42
Patent Applications:	4,640
DailyMed Link:	erythromycin estolate at DailyMed

Medical Subject Heading (MeSH) Categories for erythromycin estolate

Anti-Bacterial Agents

Enzyme Inhibitors

Gastrointestinal Agents

Protein Synthesis Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for erythromycin estolate

D10AF	Antiinfectives for treatment of acne
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

J01FA	Macrolides
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for erythromycin estolate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	ILOSONE	erythromycin estolate	SUSPENSION;ORAL	061894-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	ILOSONE	erythromycin estolate	TABLET;ORAL	061896-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	ILOSONE	erythromycin estolate	CAPSULE;ORAL	061897-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	ILOSONE	erythromycin estolate	SUSPENSION/DROPS;ORAL	061894-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Dista	ILOSONE	erythromycin estolate	FOR SUSPENSION;ORAL	061893-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Cosette Pharms Nc	ERYTHROMYCIN ESTOLATE	erythromycin estolate	SUSPENSION;ORAL	062169-001	Oct 17, 1990		DISCN	No	No

Erythromycin Estolate Market Dynamics, Financial Trajectory, Patents, and Generic Competition

Last updated: July 31, 2026

Erythromycin estolate is a legacy oral macrolide with no meaningful current branded-market franchise. Its patent protection expired decades ago, generic competition is mature, and public company filings do not disclose product-level revenue. Commercial demand has contracted because erythromycin estolate has been displaced by better-tolerated macrolides, including azithromycin and clarithromycin, and by newer antibiotics. The principal commercial issues are product availability, manufacturing economics, regulatory maintenance, and clinical substitution rather than patent exclusivity.

What is erythromycin estolate and how is it used?

Erythromycin estolate is an orally administered ester prodrug of erythromycin. It was developed to improve oral absorption and provide a practical formulation for systemic treatment of susceptible bacterial infections. Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Historical uses included:

• Upper and lower respiratory tract infections
• Streptococcal infections in patients unable to use penicillin
• Skin and soft-tissue infections
• Certain atypical bacterial infections
• Pertussis
• Selected sexually transmitted and neonatal infections

Erythromycin estolate was marketed in oral tablet, capsule, and suspension presentations under the Ilosone brand and through generic manufacturers. The formulation has a clinically important limitation: erythromycin estolate has been associated with cholestatic hepatitis. The FDA labeling identifies this risk and warns that treatment should be discontinued if symptoms of hepatitis occur (U.S. Food and Drug Administration [FDA], n.d.-a).

The drug is distinct from other erythromycin salts and esters, including erythromycin base, erythromycin ethylsuccinate, and erythromycin stearate. These products differ in absorption, tolerability, dosage form, and regulatory history.

What is the current FDA regulatory status of erythromycin estolate?

Erythromycin estolate is an established active pharmaceutical ingredient, not a new molecular entity. Its commercial status is generally that of a legacy generic product rather than an actively promoted branded medicine.

FDA regulatory characteristics include:

Regulatory characteristic	Erythromycin estolate
Drug class	Macrolide antibacterial
Route	Oral
Regulatory pathway	Historical NDA and subsequent abbreviated generic pathways
New molecular entity exclusivity	Expired
Pediatric exclusivity	Expired
Orphan exclusivity	Not a central commercial feature
Biosimilar pathway	Not applicable
Current commercial model	Generic and limited legacy supply
Primary regulatory risk	Product discontinuation, supply interruptions, and labeling maintenance

The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, historically listed erythromycin estolate products and their reference-product relationships. Current availability can vary by strength, dosage form, manufacturer, and market channel. A product appearing in historical FDA records does not establish that a particular manufacturer is actively supplying it today. FDA discontinued-product records and current labeling databases must be reviewed at the product level (FDA, n.d.-b; FDA, n.d.-c).

When did erythromycin estolate lose exclusivity?

Erythromycin estolate lost meaningful exclusivity long before the modern generic-drug market. The product was commercially established by the 1960s, and the relevant composition, formulation, and use patents have expired.

No commercially material patent exclusivity remains for the active ingredient. Current market entry is not constrained by a surviving basic patent covering erythromycin estolate.

Exclusivity category	Current position
Active-ingredient patent	Expired
Original formulation patents	Expired
Original method-of-use patents	Expired
Regulatory exclusivity	Expired
Orange Book patent protection	No current commercial barrier expected
Paragraph IV exposure	Not commercially significant for the legacy product

The absence of current patent protection means that a prospective manufacturer generally competes on FDA approval status, manufacturing cost, supply reliability, quality systems, and contracting access.

What patents protect erythromycin estolate?

No active patent estate is known to protect the legacy erythromycin estolate molecule or its historical oral formulations in the United States.

The relevant historical intellectual-property categories were:

1. Erythromycin fermentation and isolation technology.
2. Esterification of erythromycin to form erythromycin estolate.
3. Oral dosage forms and suspension formulations.
4. Therapeutic uses for bacterial infections.
5. Manufacturing and purification processes.

Those rights were filed and prosecuted primarily during the early commercial life of erythromycin products. They do not create a present-day barrier to generic development. Any new patent would need to cover a genuinely novel formulation, delivery system, manufacturing improvement, or therapeutic use and would not restore exclusivity to the old active ingredient.

Are formulation patents still relevant?

A new formulation patent could matter only if it covered a product materially different from conventional erythromycin estolate tablets, capsules, or suspensions. Potential examples could include:

• Modified-release oral delivery
• Taste-masked pediatric suspension
• Stabilized liquid formulation
• Novel solid dispersion
• Combination product
• New dosing regimen supported by clinical data

Such a patent would protect the claimed formulation, not erythromycin estolate generally. A conventional generic product could remain outside the claim scope if it used a different formulation or manufacturing process.

How many patents cover erythromycin estolate?

The commercially relevant number is effectively zero for unexpired United States patents covering the conventional product.

Historical patent counts are difficult to use as a market indicator because they include expired patents, foreign counterparts, continuations, manufacturing disclosures, and patents covering erythromycin products generally rather than erythromycin estolate specifically. Patent-family volume therefore overstates current protection.

The practical patent-strength assessment is:

Patent factor	Assessment
Core molecule protection	None remaining
Conventional oral formulation	None remaining
Use patents	Expired
Manufacturing patents	Historical only unless a new process is developed
Freedom to operate	Generally favorable for conventional generic manufacture
Litigation leverage	Low
Lifecycle-management opportunity	Limited and formulation-dependent

What is the Orange Book status of erythromycin estolate?

The Orange Book remains relevant for identifying historical reference products, dosage forms, therapeutic-equivalence evaluations, and any listed patents. For erythromycin estolate, the commercial importance of Orange Book listings is limited because the core exclusivity period has ended.

A company assessing entry should distinguish among:

• A currently marketed reference product
• A discontinued reference product
• An active abbreviated new drug application
• A product that remains approved but is not commercially supplied
• A product listed in FDA databases only for historical or regulatory purposes

The existence of an approved generic application does not guarantee active supply. Erythromycin estolate has a relatively narrow commercial base, so manufacturers may discontinue products when demand, pricing, or production economics deteriorate.

Which companies are challenging erythromycin estolate exclusivity?

There is no current high-value patent challenge comparable to litigation involving protected branded products. Generic competition occurred through ordinary abbreviated new drug application pathways after the underlying exclusivity expired.

The relevant competitive groups are:

• Legacy generic antibiotic manufacturers
• Contract manufacturers supplying hospitals and pharmacies
• Regional suppliers of oral suspensions
• Manufacturers of alternative erythromycin salts
• Suppliers of azithromycin and clarithromycin

Paragraph IV litigation is not a major current market driver. A Paragraph IV certification is most commercially relevant when an Orange Book-listed patent creates a valuable reference-product market. For erythromycin estolate, that economic foundation has largely disappeared.

What patent litigation affects erythromycin estolate?

No major current United States patent litigation is a central factor in the erythromycin estolate market.

Historical disputes involving erythromycin products may have addressed manufacturing, formulations, or competing macrolide products. Those matters do not create present-day exclusivity unless an unexpired patent remains enforceable and is relevant to the marketed product.

The current legal risk profile is more likely to involve:

• Manufacturing-process disputes
• Product liability claims related to hepatotoxicity
• FDA compliance actions
• Current good manufacturing practice deficiencies
• Supply or quality investigations
• Contract disputes
• False or misleading promotional claims

Patent litigation risk is low relative to regulatory and supply-chain risk.

What is the financial trajectory of erythromycin estolate?

Public financial data for erythromycin estolate are not separately reported by major pharmaceutical companies. The product is generally embedded in broader generic-antibiotic revenue categories, making product-level revenue, margin, and market-share estimates unavailable from public filings.

Its financial trajectory is best characterized as:

Period	Commercial condition	Financial direction
1960s-1980s	Branded and established oral macrolide	Growth and mature-product revenue
1990s	Generic entry and expanding substitution	Sharp price and margin pressure
2000s	Competition from azithromycin and clarithromycin	Volume and share erosion
2010s	Legacy generic availability with intermittent supply	Low, fragmented revenue
2020s	Limited demand and product-level disclosure	Low or immaterial revenue for most suppliers

The product’s revenue pool is constrained by four factors:

1. Therapeutic substitution. Clinicians often prefer azithromycin because of dosing convenience and improved gastrointestinal tolerability.
2. Safety concerns. Cholestatic hepatitis limits the attractiveness of erythromycin estolate.
3. Generic pricing. Multiple suppliers and low switching costs suppress pricing.
4. Manufacturing economics. Low-volume oral products may not justify continued production if API, packaging, testing, or compliance costs rise.

The product can still generate niche revenue where formulary protocols, pediatric use, local procurement, or limited alternatives support demand. That revenue is unlikely to support a large branded commercial organization.

How does erythromycin estolate compare with azithromycin and clarithromycin?

Azithromycin and clarithromycin became the principal commercial substitutes for many outpatient macrolide indications.

Attribute	Erythromycin estolate	Azithromycin	Clarithromycin
Dosing convenience	Less favorable	Generally favorable	Intermediate
Gastrointestinal tolerability	Relatively poor	Generally improved	Variable
Hepatic safety concern	Cholestatic hepatitis associated with estolate	Different safety profile	Drug interactions and hepatic concerns
Generic availability	Mature, limited-volume	Broad	Broad
Patent status	Expired	Expired core protection; formulation products vary	Expired core protection; formulation products vary
Commercial demand	Declining legacy demand	Larger generic market	Larger generic market
Current lifecycle value	Low	Moderate generic scale	Moderate generic scale

Erythromycin estolate retains clinical relevance in selected circumstances, but its commercial position is weaker because physicians can choose alternative macrolides with simpler dosing and broader contemporary use.

What generic entry risks exist for erythromycin estolate?

Generic entry risk is high in the traditional sense because there is no meaningful patent barrier. However, the market may not support aggressive entry because expected revenue is limited.

Commercial entry risks

• Small addressable market
• Low unit prices
• Established generic competitors
• Hospital and wholesaler contracting pressure
• Inventory carrying costs
• Product-specific demand volatility
• Potentially limited API sources
• Low return on regulatory and validation investment

Regulatory and manufacturing barriers

Manufacturers must maintain compliance with FDA requirements for:

• API identity, strength, quality, and purity
• Oral suspension uniformity and stability
• Dissolution and bioequivalence
• Microbial controls
• Container-closure integrity
• Stability data
• Labeling for hepatic adverse reactions
• Current good manufacturing practice

The principal barrier is not intellectual property. It is the ability to produce the product consistently at a cost that supports continued supply.

Is biosimilar competition relevant to erythromycin estolate?

No. Biosimilars apply to biological products, while erythromycin estolate is a chemically synthesized or fermentation-derived small-molecule antibiotic regulated through conventional drug approval pathways. The relevant competitors are generic drugs, alternative erythromycin salts, and other macrolide antibiotics.

What licensing deals involve erythromycin estolate?

No major current licensing transaction centered on erythromycin estolate is publicly associated with the product’s commercial market. Historical rights were linked to the original branded erythromycin business and later generic supply arrangements.

A modern transaction involving the product would more likely be:

• A product-rights transfer
• A contract-manufacturing agreement
• A regional distribution arrangement
• A portfolio acquisition involving multiple legacy antibiotics
• An API supply agreement

The low price and limited market size reduce the likelihood of a standalone, high-value licensing deal.

What generic launch scenarios are plausible?

Three scenarios are commercially plausible:

Continued niche supply

One or more manufacturers maintain the product for formulary, pediatric, or regional demand. Prices remain low, and supply may be intermittent.

Further market contraction

Manufacturers discontinue the product because of low volume, quality costs, or API constraints. Prescribers shift to other macrolides or alternative antibiotics.

Reformulated niche product

A manufacturer develops a differentiated pediatric suspension, taste-masked product, or stable liquid formulation. Commercial success would depend on regulatory approval, clinical acceptance, and reimbursement rather than the old erythromycin estolate patent estate.

What is the geographic coverage of erythromycin estolate protection?

The original patent rights have expired in major pharmaceutical markets, including the United States and other jurisdictions where erythromycin estolate was historically commercialized. Current geographic differences concern regulatory approvals, local product registrations, procurement practices, and manufacturing availability.

A global launch would require separate evaluation of:

• National marketing authorizations
• Local reference-product requirements
• Pharmacopoeial standards
• Import and API controls
• Pediatric labeling
• Government procurement
• Local patent status for any new formulation

The conventional product has no credible global patent moat. A new formulation would require country-by-country patent and regulatory analysis.

How strong is the patent estate for erythromycin estolate?

The patent estate is weak for conventional products and commercially irrelevant for core exclusivity. A prospective entrant should focus its diligence on regulatory status, manufacturing feasibility, supply continuity, and customer demand.

Investment criterion	Rating
Patent protection	Very low
Regulatory exclusivity	None expected
Generic competition	High
Pricing power	Very low
Supply-chain opportunity	Possible
Branded relaunch potential	Low
Reformulation opportunity	Limited but possible
Litigation exposure	Low patent risk; regulatory and product-liability risk remain

Key Takeaways

• Erythromycin estolate is a mature, off-patent oral macrolide.
• Its original patent and regulatory exclusivity have expired.
• No active patent estate is expected to block conventional generic entry.
• Paragraph IV litigation is not a significant current market issue.
• Product-level revenue is not separately disclosed by major companies.
• Financial performance has followed a long-term decline driven by generic pricing and substitution by azithromycin and clarithromycin.
• The principal risks are product discontinuation, manufacturing economics, supply reliability, and adverse-effect concerns.
• Any remaining commercial opportunity is niche and depends on dependable supply or a differentiated formulation.
• Biosimilar competition is irrelevant because erythromycin estolate is a small-molecule drug.
• A new formulation could create limited, claim-specific protection, but it would not restore exclusivity to conventional erythromycin estolate.

FAQs About Erythromycin Estolate Market Exclusivity and Competition

Is erythromycin estolate still commercially available?

Availability varies by dosage form, strength, manufacturer, and country. Historical FDA approval or Orange Book listing does not guarantee that a product is actively supplied.

Does erythromycin estolate have a live U.S. patent?

No commercially meaningful patent protection is expected for the conventional erythromycin estolate molecule or its historical oral formulations.

Can a company launch a generic erythromycin estolate product?

A company could pursue a conventional generic pathway if it satisfies FDA approval, bioequivalence, manufacturing, labeling, and supply requirements. The main challenge is commercial viability rather than patent clearance.

Why did erythromycin estolate lose market share?

The product faced generic price erosion, gastrointestinal tolerability concerns, cholestatic hepatitis risk, and substitution by azithromycin and clarithromycin.

Could a new erythromycin estolate formulation receive patent protection?

Yes. A genuinely novel formulation, delivery system, manufacturing process, or supported dosing method could receive patent protection. The protection would apply only to the claimed innovation and not to conventional erythromycin estolate products.

References

1. U.S. Food and Drug Administration. (n.d.-a). Erythromycin estolate prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. FDA.

4. U.S. Food and Drug Administration. (n.d.-d). Federal Food, Drug, and Cosmetic Act: Abbreviated new drug applications and patent certifications. FDA.

5. DailyMed. (n.d.). Erythromycin estolate product labeling. National Library of Medicine.